De­sign Ther­a­peu­tics hints at ‘strate­gic re­align­ment,’ re­places CEO; Karyopharm co-founder leads AT­P's Nereid

De­sign Ther­a­peu­tics chair­man Pratik Shah has suc­ceed­ed João Sif­fert as CEO while teas­ing a “strate­gic re­align­ment” that won’t be re­vealed un­til ear­ly 2024, ac­cord­ing to its Q3 re­port. De­sign does elab­o­rate on the sta­tus of its cash run­way, which is pro­ject­ed to keep the lights on “through 2028” as a re­sult of the changes. Shah has chaired the board since 2017 and is con­nect­ed to two Lau­ra Shawver biotechs as the ex-chair­man of Syn­thorxpur­chased by Sanofi — and the cur­rent chair­man at ARS Phar­ma­ceu­ti­cals, which merged with Shawver-led Sil­ver­back Ther­a­peu­tics last year. Sif­fert took the top spot at De­sign in Oc­to­ber 2020 af­ter re­sign­ing as CEO, head of R&D and CMO at Abeona Ther­a­peu­tics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.